The Impact of Gender-Affirming Hormone Therapy on Physical Performance
The Journal of Clinical Endocrinology & Metabolism · 18.01.2024 · 109 (2) · e455-e465
DOI: 10.1210/clinem/dgad414 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 13.07.2023. Verfasst von Ada S Cheung und 6 weiteren Autor:innen. Beteiligte Einrichtung: Trans Health Research Group, Department of Medicine (Austin Health), The University of Melbourne, Melbourne 3084, Australia. Hauptthemen laut MEDLINE: Transsexualism, Transgender Persons. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHMRC Investigator Grant, NHMRC.
Abstract (Originalsprache)
Context
The inclusion of transgender people in elite sport has been a topic of debate. This narrative review examines the impact of gender-affirming hormone therapy (GAHT) on physical performance, muscle strength, and markers of endurance. Evidence Acquisition MEDLINE and Embase were searched using terms to define the population (transgender), intervention (GAHT), and physical performance outcomes. Evidence Synthesis Existing literature comprises cross-sectional or small uncontrolled longitudinal studies of short duration. In nonathletic trans men starting testosterone therapy, within 1 year, muscle mass and strength increased and, by 3 years, physical performance (push-ups, sit-ups, run time) improved to the level of cisgender men. In nonathletic trans women, feminizing hormone therapy increased fat mass by approximately 30% and decreased muscle mass by approximately 5% after 12 months, and steadily declined beyond 3 years. While absolute lean mass remains higher in trans women, relative percentage lean mass and fat mass (and muscle strength corrected for lean mass), hemoglobin, and VO2 peak corrected for weight was no different to cisgender women. After 2 years of GAHT, no advantage was observed for physical performance measured by running time or in trans women. By 4 years, there was no advantage in sit-ups. While push-up performance declined in trans women, a statistical advantage remained relative to cisgender women.
Conclusion
Limited evidence suggests that physical performance of nonathletic trans people who have undergone GAHT for at least 2 years approaches that of cisgender controls. Further controlled longitudinal research is needed in trans athletes and nonathletes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Trans Health Research Group, Department of Medicine (Austin Health), The University of Melbourne, Melbourne 3084, Australia.
- Department of Endocrinology, Austin Health, Heidelberg 3084, Australia.
- Institute for Health and Sport (IHeS), Victoria University, Footscray 3011, Australia.
- Australian Regenerative Medicine Institute, Monash University, Clayton 3800, Australia.
ORCID-Profile: Ada S Cheung, Sav Zwickl, Brendan J Nolan, Alex Fang Qi Wong, Patrice Jones, Nir Eynon
Förderung
- NHMRC Investigator Grant
- NHMRC
Zitieren
APA
Cheung, A. S., Zwickl, S., Miller, K., Nolan, B. J., Wong, A. F. Q., Jones, P., & Eynon, N. (2024). The Impact of Gender-Affirming Hormone Therapy on Physical Performance. The Journal of Clinical Endocrinology & Metabolism, 109(2), e455-e465. https://doi.org/10.1210/clinem/dgad414
Vancouver
Cheung AS, Zwickl S, Miller K, Nolan BJ, Wong AFQ, Jones P, et al. The Impact of Gender-Affirming Hormone Therapy on Physical Performance. The Journal of Clinical Endocrinology & Metabolism. 2024;109(2):e455-e465. doi:10.1210/clinem/dgad414
BibTeX
@article{Cheung2024,
author = {Cheung, Ada S and Zwickl, Sav and Miller, Kirsti and Nolan, Brendan J and Wong, Alex Fang Qi and Jones, Patrice and Eynon, Nir},
title = {The Impact of Gender-Affirming Hormone Therapy on Physical Performance},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
volume = {109},
number = {2},
pages = {e455--e465},
doi = {10.1210/clinem/dgad414}
}
EUVIMED